# Phase 2 Study: OBI-833/OBI-821 Maintenance for Globo H+ Advanced Biliary Tract Cancer After Gemcitabine/Cisplatin

> **NCT06490198** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Chang Gung Memorial Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Cholangiocarcinoma
- Chemotherapy Effect
- Immunotherapy

## Interventions

- **DRUG:** OBI-833/OBI-821

## Key facts

- **NCT ID:** NCT06490198
- **Lead sponsor:** Chang Gung Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-31
- **Primary completion:** 2026-07-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06490198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06490198, "Phase 2 Study: OBI-833/OBI-821 Maintenance for Globo H+ Advanced Biliary Tract Cancer After Gemcitabine/Cisplatin". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06490198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*